Inhibrx Biosciences, Inc. (INBX): Total Liabilities
$138.49M
As of 2025-12-31
$207.20M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $138.49M | +193.5% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $47.18M | -82.2% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $264.39M | n/a | 2025-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $138.49M | +193.5% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| Prokidney Corp. (PROK) | 2025-12-31 | $34.78M | -11.8% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $113.26M | -40.6% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
Compare INBX, OTLK, PROK, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗